Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
Royal Marsden NHS Foundation Trust
Institut Bergonié
H. Lee Moffitt Cancer Center and Research Institute
Royal Marsden NHS Foundation Trust
Institut Bergonié
Washington University School of Medicine
Institut Bergonié
National Taiwan University Hospital
Lytix Biopharma AS
Medical College of Wisconsin
National Cancer Institute (NCI)
Institut Bergonié
Institut Bergonié
University of Michigan Rogel Cancer Center
Dana-Farber Cancer Institute
Medical University of South Carolina
Massachusetts General Hospital
Eli Lilly and Company
Massachusetts General Hospital
Institut Bergonié
Ipsen
Columbia University
ImmunoGenesis
National Institutes of Health Clinical Center (CC)
Intensity Therapeutics, Inc.
Ipsen
Sarcoma Oncology Research Center, LLC
Ann & Robert H Lurie Children's Hospital of Chicago
National Cancer Institute (NCI)
Stanford University
BeiGene
National Cancer Institute (NCI)
TopAlliance Biosciences
Eli Lilly and Company
Mundipharma Research Limited
Washington University School of Medicine
Fred Hutchinson Cancer Center
Columbia University
University of Miami
Hutchmed
University of Iowa
University of Iowa
ImmunityBio, Inc.
ImmunityBio, Inc.
Hutchmed
ImmunityBio, Inc.